Browse
Submit Data
Databases
API
Help

Dataset Information

5 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A study to examine the side effects and benefits during marketing phase of Hetero - Bevacizumab in cancer patients

ABSTRACT: Primary outcome(s): Incidence, severity, outcome, duration, action taken, and causality of individual adverse events [Expected and Unexpected adverse events (Serious and Non-serious Adverse Events)] reported during the studyTimepoint: All time points

DISEASE(S): Malignant Neoplasm Of Frontal Lobe,Metastatic Colorectal Cancer, Non-squamous Nonâ??small Cell Lung Cancer, Glioblastoma, Metastatic Renal Cell Carcinoma And Persistent, Recurrent, Or Metastatic Carcinoma Of The Cervix,Malignant Neoplasm Of Colon, Unspecified,Malignant Neoplasm Of Unspecifiedkidney, Except Renal Pelvis,Malignant Neoplasm Of Cervix Uteri, Unspecified,Malignant Neoplasm Of Unspecifiedpart Of Bronchus Or Lung

PROVIDER: 2584044 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain

Project description:Primary objectives: To compare alvimopan with placebo for long-term safety and tolerability Primary endpoints: Incidence of reported clinical adverse events, including serious and non-serious adverse events as well as treatment-limiting adverse events

| 2517464 | ecrin-mdr-crc

Beyond the polymerase-gamma theory: Respiratory chain inhibition and production of ROS as modes of NRTI induced mitochondrial toxicity

Project description:HIV-1 nucleoside reverse transcriptase inhibitor (NRTI) use is associated with severe adverse events. However, the exact mechanisms behind their toxicity has not been fully understood. Mitochondrial dysfunction after chronic exposure to NRTIs has predominantly been assigned to mitochondrial polymerase- inhibition by NRTIs. However, an increasing amount of data suggests that this is not the sole mechanism. Many NRTI induced adverse events have been linked to the incurrence of oxidative stress, although the causality of events leading to reactive oxygen species (ROS) production and their role in toxicity is unclear. In this study we show that short-term effects of these drugs, which are rarely discussed in the literature, include direct inhibition of the mitochondrial respiratory chain (MRC), decreased ATP levels and increased ROS production. Collectively these events affect fitness and longevity of C. elegans through mitohormetic signalling events. Furthermore, we demonstrate that these effects can be normalized by addition of the anti-oxidant N-acetylcysteine (NAC), which suggests that ROS likely influence the onset and severity of adverse events upon drug exposure.

2018-02-13 | GSE100482 | GEO

hR3 in metastatic or recurrent colorectal cancer

Project description:Interventions: Group I (Experimental): Nimotuzumab (hR3) 200 mg. Grupo II (Experimental): Nimotuzumab (hR3) 400 mg. Grupo III (Experimental): Nimotuzumab (hR3) 800 mg. Grupo IV (Experimental): Nimotuzumab (hR3) 1200 mg. Nimotuzumab Indication: weekly, for 7 weeks then every 2 weeks (intravenous infusion) by 24 month or until significant toxicity. Primary outcome(s): Incidence of Adverse Events (AE) relating to the administration of Nimotuzumab (AE with causal relationship probable or very likely). Measuring time: in every administration until to complete 2 years of treatment. •Type of AE (name of the adverse event) •Duration of AE (Difference between of start date and the end date of the AE. May be in days, hours or minutes) •Intensity of AE (mild, moderate, severe, Life threatening, death related) •Serious AE (Severe/Serious, not serious/not serious) •Attitude from study treatment (unchanged, dose modification, temporary discontinuation of study treatment, permanent discontinuation of study treatment) •Result of AE (recovered, improved, persist, sequelae) •Causality of the adverse event (Certain, Probable /Likely, Possible, Unlikely, Unrelated) Study Design: Allocation: N/A: single arm study. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment

| 2571517 | ecrin-mdr-crc

A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects.

Project description:Primary objectives: To compare the safety among the treatment regimens, while offering continued access to blinded investigational product to subjects who have completed a prior GSK alvimopan OBD study in cancer pain subjects. Primary endpoints: Incidence of reported adverse events, including serious adverse events.

| 2515918 | ecrin-mdr-crc

Phase I/II study of immuntoxin for treatment of metastatic abdominaldisease in patient with colorectal cancer.

Project description:Primary objectives: To assess safety and toxicity (Dose Limiting Toxicity) after intraperitoneal administration of MOC31PE. Primary endpoints: Frequency and severity of adverse events and serious adverse events.The NCI Common Terminology Criteria for Adverse Events Version 4.0(CTCAE) will be used.Changes in laboratory values, vital signs and ECOG performance statuswill also be assessed.

| 2531813 | ecrin-mdr-crc

Adoptive cell therapy across cancer diagnoses

Project description:Primary objectives: The main objective is to determine the feasibility and safety of adoptive cell therapy in combination with checkpoint inhibition across different metastatic solid cancers. Primary endpoints: Toxicity: Registration of all AEs and unexpected events in relation to the treatment will be done in accordance with the common terminology criteria for adverse events (CTCAE) criteria as described in appendix 3.

| 2537065 | ecrin-mdr-crc

Single-cell sequencing of T cells prepared by different methods

Project description:We successfully develop a two-in-one approach to generate non-viral genome specific targeted CAR T cells through CRISPR/Cas9. In the adoptive therapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, we observed durable responses without serious adverse events and complete remission in patients treated with these PD1 knockout CAR T cells. Here we applied single-cell sequencing to analyze the characteristcis of T cells prepared by different methods.

2022-06-20 | GSE186596 | GEO

Single-cell sequencing of infusion products and T cells after administration of non-viral PD1-targeted anti-CD19 CAR T cells

Project description:We successfully developed a two-in-one approach to generate non-viral genome specific targeted CAR T cells through CRISPR/Cas9. In the adoptive therapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, we observed durable responses without serious adverse events and complete remission in patients treated with PD1 knockin CAR T cells. Here we applied single-cell sequencing to analyze the characteristcis of infusion products and T cells after administration.

2022-06-20 | GSE166352 | GEO

TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC

Project description:Primary Objective: To determine disease control rate (DCR) of TS-1 in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: * To determine objective response rate (ORR) * To determine time to progression (TTP) * To determine overall survival (OS) * To assess incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]

| 2272349 | ecrin-mdr-crc

A clinical study of TG6002 and flucytosine in patients with gastro-intestinal tumors

Project description:Primary objectives: Phase I: determination of the recommended phase II dose Phase IIa: efficacy of multiple administrations of TG6002 in combination with flucytosine (or Ancotil or 5-FC) Primary endpoints: Phase I: adverse events, serious adverse events, change in standard laboratory parameters and vital signs, dose-limiting toxicities. Phase IIa: overall response rate.

| 2537744 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data